Xenon Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Xenon Pharmaceuticals's earnings have been declining at an average annual rate of -38.6%, while the Biotechs industry saw earnings growing at 12.3% annually. Revenues have been declining at an average rate of 3.7% per year.
Key information
-38.6%
Earnings growth rate
-17.4%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -3.7% |
Return on equity | -19.7% |
Net Margin | n/a |
Next Earnings Update | 09 May 2024 |
Recent past performance updates
Recent updates
Calculating The Fair Value Of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)
Apr 16Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Mar 12Xenon Pharmaceuticals: Analysts Still Positive Despite Recent Trial 'Setbacks'
Feb 08Here's Why We're Not Too Worried About Xenon Pharmaceuticals' (NASDAQ:XENE) Cash Burn Situation
Oct 21We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Jun 22We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Feb 15We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Oct 27Xenon started at outperform at Raymond James on experimental epilepsy drug
Oct 19Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Could Be 31% Below Their Intrinsic Value Estimate
Sep 22Putting Xenon Pharmaceuticals Back In The Spotlight
Sep 06Xenon initiated with Buy at BofA citing potential of anti-seizure drug
Aug 29Xenon Pharmaceuticals Inc.'s (NASDAQ:XENE) Intrinsic Value Is Potentially 67% Above Its Share Price
Jun 13Sizing Up Xenon Pharmaceuticals
Dec 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Nov 12We Think Xenon Pharmaceuticals (NASDAQ:XENE) Can Afford To Drive Business Growth
Aug 05Industry Analysts Just Upgraded Their Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Revenue Forecasts By 6.4%
May 13We're Hopeful That Xenon Pharmaceuticals (NASDAQ:XENE) Will Use Its Cash Wisely
Apr 14Is Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Popular Amongst Institutions?
Mar 16Revenue & Expenses BreakdownBeta
How Xenon Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -182 | 47 | 0 |
30 Sep 23 | 0 | -175 | 42 | 0 |
30 Jun 23 | 0 | -164 | 38 | 0 |
31 Mar 23 | 1 | -147 | 36 | 0 |
31 Dec 22 | 9 | -126 | 33 | 0 |
30 Sep 22 | 13 | -113 | 31 | 0 |
30 Jun 22 | 21 | -91 | 27 | 0 |
31 Mar 22 | 23 | -83 | 25 | 0 |
31 Dec 21 | 18 | -81 | 22 | 0 |
30 Sep 21 | 20 | -66 | 18 | 0 |
30 Jun 21 | 18 | -59 | 17 | 0 |
31 Mar 21 | 29 | -37 | 14 | 0 |
31 Dec 20 | 32 | -29 | 13 | 0 |
30 Sep 20 | 30 | -28 | 13 | 0 |
30 Jun 20 | 27 | -28 | 13 | 0 |
31 Mar 20 | 14 | -38 | 12 | 0 |
31 Dec 19 | 7 | -42 | 11 | 0 |
30 Sep 19 | 4 | -39 | 10 | 0 |
30 Jun 19 | 0 | -44 | 9 | 0 |
31 Mar 19 | 0 | -42 | 9 | 0 |
31 Dec 18 | 0 | -34 | 8 | 0 |
30 Sep 18 | 0 | -34 | 8 | 0 |
30 Jun 18 | 0 | -27 | 8 | 0 |
31 Mar 18 | 0 | -27 | 7 | 0 |
31 Dec 17 | 0 | -31 | 7 | 0 |
30 Sep 17 | 1 | -29 | 7 | 4 |
30 Jun 17 | 1 | -29 | 7 | 10 |
31 Mar 17 | 1 | -27 | 7 | 15 |
31 Dec 16 | 2 | -23 | 7 | 19 |
30 Sep 16 | 5 | -21 | 7 | 18 |
30 Jun 16 | 9 | -17 | 6 | 16 |
31 Mar 16 | 12 | -10 | 5 | 14 |
31 Dec 15 | 16 | -16 | 10 | 12 |
30 Sep 15 | 17 | -2 | 10 | 11 |
30 Jun 15 | 26 | 5 | 10 | 9 |
31 Mar 15 | 27 | 4 | 11 | 7 |
31 Dec 14 | 28 | 13 | 5 | 6 |
30 Sep 14 | 29 | 6 | 5 | 4 |
30 Jun 14 | 27 | 4 | 5 | 4 |
31 Mar 14 | 27 | 4 | 5 | 5 |
31 Dec 13 | 27 | 4 | 5 | 6 |
30 Sep 13 | 25 | 0 | 6 | 6 |
30 Jun 13 | 17 | -3 | 6 | 6 |
Quality Earnings: XENE is currently unprofitable.
Growing Profit Margin: XENE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: XENE is unprofitable, and losses have increased over the past 5 years at a rate of 38.6% per year.
Accelerating Growth: Unable to compare XENE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: XENE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: XENE has a negative Return on Equity (-19.66%), as it is currently unprofitable.